Sage Rhino Capital LLC Cuts Stock Position in Sanofi (NASDAQ:SNY)

Sage Rhino Capital LLC lowered its position in Sanofi (NASDAQ:SNY) by 5.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,206 shares of the company’s stock after selling 516 shares during the period. Sage Rhino Capital LLC’s holdings in Sanofi were worth $408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Rise Advisors LLC grew its position in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the last quarter. Salem Investment Counselors Inc. purchased a new stake in Sanofi during the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC grew its position in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the last quarter. CNB Bank purchased a new stake in Sanofi during the 3rd quarter worth approximately $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA grew its position in Sanofi by 115.6% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock worth $37,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on SNY. Morgan Stanley began coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Finally, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Trading Up 0.3 %

SNY traded up $0.14 during midday trading on Tuesday, hitting $49.23. The company’s stock had a trading volume of 3,182,534 shares, compared to its average volume of 2,021,368. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a market cap of $124.53 billion, a P/E ratio of 24.74, a PEG ratio of 1.48 and a beta of 0.61. The firm has a 50-day moving average price of $47.82 and a two-hundred day moving average price of $48.25. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.93.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The company had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. On average, research analysts anticipate that Sanofi will post 4.09 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio is presently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.